Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis [Phase 1]

View source ↗

Summary

This clinical trial update outlines a Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in partici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• P-CD19CD20-ALLO1

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Sclerosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING